DEXBROMPHENIRAMINE MALEATE

US Approved OTC

First approved in 1959

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H19BrN2.C4H4O4
Molecular Weight	435.312
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C/C(O)=O.CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C2=NC=CC=C2

InChI

InChIKey=SRGKFVAASLQVBO-DASCVMRKSA-N

InChI=1S/C16H19BrN2.C4H4O4/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-9,11,15H,10,12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C16H19BrN2
Molecular Weight	319.239
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C4H4O4
Molecular Weight	116.0722
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a3b34f38-87da-4a38-ac73-66d28cc8647e&type=display | https://pubchem.ncbi.nlm.nih.gov/compound/Dexbrompheniramine

DEXBROMPHENIRAMINE is an alkylamine derivative with anticholinergic and sedative properties. It is a histamine H1-receptor antagonist that competes with histamine for the H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. The antagonistic action of this agent blocks the activities of endogenous histamine, which subsequently leads to temporary relief from the negative histamine-mediated symptoms of an allergic reaction such as bronchoconstriction, vasodilation, increased capillary permeability and spasmodic contractions of the gastrointestinal smooth muscle. DEXBROMPHENIRAMINE as a part of combination medicine is used to treat symptoms of the common cold or seasonal allergies, including sneezing, runny or stuffy nose, and itchy, watery eyes.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 316 Target ID: CHEMBL231 Sources: https://www.drugbank.ca/drugs/DB00405 \| https://www.ncbi.nlm.nih.gov/pubmed/6634989	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Common cold 58 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3b34f38-87da-4a38-ac73-66d28cc8647e	Palliative		Approved 8583	PANATUSS PEDIATRIC DROPS DXP Approved Use Uses: - Temporarily relieves cough due to minor throat and bronchial irritations as may occur with the common cold; - Temporarily relieves nasal congestions due to common cold; - For temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or allergic rhinitis. Launch Date 2005
Allergic rhinitis 104 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3b34f38-87da-4a38-ac73-66d28cc8647e	Palliative		Approved 8583	PANATUSS PEDIATRIC DROPS DXP Approved Use Uses: - Temporarily relieves cough due to minor throat and bronchial irritations as may occur with the common cold; - Temporarily relieves nasal congestions due to common cold; - For temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or allergic rhinitis. Launch Date 2005

C_max

Value	Dose	Co-administered	Analyte	Population
27.98 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3981411/	6 mg 2 times / day steady-state, oral dose: 6 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXBROMPHENIRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
234.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3981411/	6 mg 2 times / day steady-state, oral dose: 6 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXBROMPHENIRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
22 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3981411/	6 mg 2 times / day steady-state, oral dose: 6 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXBROMPHENIRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
0.3 % 1 times / day steady, ophthalmic Recommended Dose: 0.3 %, 1 times / day Route: ophthalmic Route: steady Dose: 0.3 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1687324/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/1687324/	Sources: https://pubmed.ncbi.nlm.nih.gov/1687324/
6 mg 4 times / day steady, oral Recommended Dose: 6 mg, 4 times / day Route: oral Route: steady Dose: 6 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3981411/	healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3981411/	Sources: https://pubmed.ncbi.nlm.nih.gov/3981411/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:59269	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:59269
ChemicalBook	CB6164683	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6164683
ZINC	ZINC000000000096	http://zinc15.docking.org/substances/ZINC000000000096

PubMed

Title	Date	PubMed
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures.	2001 Apr	11340978
Non-antibiotic treatments for upper-respiratory tract infections (common cold).	2005 Dec	16291073
Potentialities of ITP-CZE method with diode array detection for enantiomeric purity control of dexbrompheniramine in pharmaceuticals.	2008 Apr 14	17618074
Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine.	2008 Dec	19085565
Possibilities of column coupling electrophoresis provided with a fiber-based diode array detection in enantioselective analysis of drugs in pharmaceutical and clinical samples.	2008 Jan 25	17905259
Acute cough: a diagnostic and therapeutic challenge.	2009 Dec 16	20015366
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003

Patents

Sample Use Guides

In Vivo Use Guide

Children 6 years of age to under 12 years; 2 mL every 4 - 6 hours.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:33:48 GMT 2025` Edited by `admin` on `Mon Mar 31 17:33:48 GMT 2025`
Record UNII	BPA9UT29BS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DEXBROMPHENIRAMINE MALEATE

Common Name

English

BROMPHENIRAMINE D-FORM MALEATE

Preferred Name

English

DEXBROMPHENIRAMINE MALEATE [USP MONOGRAPH]

Common Name

English

(+)-2-(P-BROMO-.ALPHA.-(2-(DIMETHYLAMINO)ETHYL)BENZYL)PYRIDINE MALEATE (1:1)

Common Name

English

DISOMER

Brand Name

English

BROMPHERIL COMPONENT DEXBROMPHENIRAMINE MALEATE

Common Name

English

BROMPHENIRAMINE D-FORM MALEATE [MI]

Common Name

English

DEXBROMPHENIRAMINE MALEATE [MART.]

Common Name

English

DRIXORAL PLUS COMPONENT DEXBROMPHENIRAMINE MALEATE

Common Name

English

DISOPHROL COMPONENT DEXBROMPHENIRAMINE MALEATE

Common Name

English

DEXBROMPHENIRAMINE MALEATE [VANDF]

Common Name

English

DEXBROMPHENIRAMINE MALEATE [USP-RS]

Common Name

English

DISOBROM COMPONENT DEXBROMPHENIRAMINE MALEATE

Common Name

English

DRIXORAL COMPONENT DEXBROMPHENIRAMINE MALEATE

Common Name

English

DEXBROMPHENIRAMINE MALEATE [ORANGE BOOK]

Common Name

English

2-PYRIDINEPROPANAMINE, G-(4-BROMOPHENYL)-N,N-DIMETHYL-, (S)-, (Z)-2-BUTENEDIOATE (1:1)

Common Name

English

Dexbrompheniramine maleate [WHO-DD]

Common Name

English

RESPORAL COMPONENT DEXBROMPHENIRAMINE MALEATE

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 341.12